(Last update: May 23, 1999)

Professor and Chairman :
Takeo KATO, MD, PhD

Associate Professor and Vice Chairman:

Assistant Professors:
Makoto DAIMON, MD, PhD (Manager of Administrative Affair)
Tomohiro HAYASHI, MD, PhD (Vice Manager of Administrative Affair and Manager of Clerical Affair)

Hideyuki EGUCHI, MD, PhD (Chief of in-patient clinic)
Toru KAWANAMI, MD, PhD (Chief of out-patient clinic)
Masahiko IGARASHI, MD, PhD
Katushi TAJIMA, MD, PhD
Hiroshi OHNUMA, MD, PhD

Adjunct Instructors:
Hideo SASAKI, MD, PhD (Professor Emeritus of our University)
Masao HARA, MD, PhD (Chief Inspector of Public Health Insurance of Yamagata Prefecture)
Tetsuyuki KITAMATO, MD, PhD (Professor of Tohoku University)
Yasuto ITOYAMA, MD, PhD (Professor of Tohoku University)
Akira MIURA, MD, PhD (Professor of Akita University)


The Third Department of Internal Medicine was founded in April, 1976 and began clinical activity in October, 1976. Our department is specialized for endocrinology, metabolism, neurology and hematology. Over 6500 patients have been admitted to our department from 1977 to 1995. So far, over 100 graduates from medical schools, mostly our Medical School, have joined our department and have been continuing clinical training as well as research works. We have held many medical meetings including the 34th Annual Meeting of Japan Diabetes Association under the presidency of Professor Sasaki. In August, 1997, Dr. Takeo Kato became the successor to the Professor and Chairman of our department ; the former Prof. Hideo Sasaki retired in March 1997. Prof. Kato specializes in neurology, and also conducts every clinical and research work of our department.

Educational and research activities

Medical students take lectures of the specialized fields of the department of internal medicine and the bed-side practical training to deepen their knowledge of diseases. Graduates are trained as a physician in the University Hospital or its affiliated hospitals at first, and then they polish up their specialties as an endocrinologist, diabetologist, neurologist or hematologist. The main purpose of the department is to produce highly refined physicians with specialized skills and broad vision. Postgraduate students conduct research works for endocrinology, metabolism, neurology or hematology under the supervision of the specialists.

Research works of our department are summarized as follows:

A. Neurology
Neurologists of the department are contributing a great deal to the understanding of pathomechanisms of neurodegenerative diseases, especially Alzheimerâćs disease and motor neuron disease. In addition to classic neuropathological and immunohistochemical studies, in situ hybridization, protein purification and sequencing, molecular biology, and clinical neurology using magnetic stimulation methods, are employed as new strategies for the study of neurodegnerative diseases.

B. Endocrinology and metabolism
Diabetes mellitus is a disease of heterogeneous causes and, therefore, the cause-oriented treatment is expected. Along with this line, we focus on the clinical involvement of brain-gut peptides, the role of the central nervous system in glucoregulation, pathophysiology of insulin resistance and extrapancreatic regulation of insulin secretion. We conduct a field survey for diabetes every year in two different communitities in Yamagata. We also search for genetical back ground of diabetes mellitus, and genetical abnormalities of many metabolic diseases such as acute intermittent porphyria and hereditary ceruloplasmin deficiency.

C. Hematology
One of our main themes in hematology is to clarify pathophysiology of thrombotic diseases. The mechanisms of platelet adhesion and aggregation are investigated by means of molecular biological techniques. Our recent research interests are focused on the interaction of thrombospondin and platelet surface molecules. Clinical studies on diabetic patients are also proceeding for the purpose of prevention of thrombotic diseases. The other topic is treatment of leukemia. Flow-cytometry is used for the analysis of cell cycle of leukemia cells, and is applied for the selection of more sensitive antileukemic agents.

References (published in 1997 and 1998, written in English)

  1. Kato T., et al: Three-dimensional conformation of the epitopes of human superoxide dismutase-2 recognized by antibody against HIV-1p17. International J of Molecular Medicine, 1:63-66, 1998
  2. Arawaka S., et al: A novel autoantibody in paraneoplastic sensory-dominant neuropathy reacts with brain-type creatine kinase. International J of Molecular Medicine, 1:597-600, 1998
  3. Kawanami T., et al: The pallidoreticular pattern of brain damage on MRI in a patient with carbon monoxide poisoning. J of Neurology, Neurosurgery & Psychiatry, 64(2) : 282, 1998
  4. Daimon M., et al: Hyperglycemia is a factor for an increase in serum ceruloplasmin in type 2 diabetes. Diabetes Care, 21(9) : 1525-1528, 1998
  5. Susa S., et al: Identification of a novel mutation of the CPO gene in a Japanese hereditary coproporphyria family. Am J of Medical Genetics, 80: 204-206, 1998
  6. Susa S., et al: A novel mutation of coproporphyrinogen oxidase (CPO) gene in a Japanese family. J Hum Genet, 43: 182-184, 1998
  7. Yamatani K, et al: Impaired vagus nerve-mediated control of insulin secretion in wistar fatty rats. Metabolism, 47(10) : 1167-1173, 1998
  8. Yamatani K., et al: Relative contribution of Ca2+-dependent mechanism in glucose-induced glucose output from the liver. Archives of Biochemistry and Biophysics, 355(2) : 175-180, 1998
  9. Tajima K., et al: Cellular localization of interleukin-5 expression in rectal carcinoma with eosinophilia. Human Pathology, 29 (9) : 1024-1028, 1998
  10. Tajima K., et al: Multiple inflammatory pseudotumors of the liver associated with acute myeloblastic leukemia. Internal Medicine, 37 (6) : 542-545, 1998
  11. Suzuki K., et al: Novel point mutation in the leucine-rich motif of the platelet glycoprotein IX associated with Bernard-Soulier syndrome. British J Hematology, 97: 794-800, 1997
  12. Manaka Y., et al: Sequential changes in CGRP-like immunoreactivity in NIDDM model Otsuka long-evans Tokushima fatty (OLETF) rat pancreatic islets. Pancreas, 17(1) : 72-79, 1997
  13. Wada M., et al: Gadolinium-enhancement of the spinal posterior roots in acute sensory ataxic neuropathy. Neurology, 49: 1470-1471, 1997
  14. Kato T., et al: Antibodies to the HIV-1p17 protein cross-react with human superoxide dismutase-2. Biochem. Biophys. Res. Commun. 230: 184-187, 1997
  15. Kato T., et al: Hereditary ceruloplasmin deficiency: A cerebro-retino-diabetic disease. Neuropathol. 17: 71-75, 1997
  16. Kato T., et al: Islet changes in hereditary ceruloplasmin deficiency. Hum Pathol 28: 499-502, 1997
  17. Watanabe M., et al: A novel missense point mutation (S134N) of the Cu/Zn superoxide dismutase gene in a patient with familial amyotrophic lateral sclerosis. Hum. Mutation 9: 69-71, 1997
  18. Arawaka S., et al: A novel autoantibody in paraneoplastic sensory-domin ant neuropathy. Neuropathol. 17: 89-93, 1997
  19. Kurita K., et al: Ultrastructural localization of heparan sulfate-like immunoreactivity in spinal spheroids of motor neuron disease. Neuropathol. 17: 15-20, 1997
  20. Kato T., et al: Binding of IDPN to rat spinal cord: its possible implication in the mechanism of spheroid formation in amyotrophic lateral sclerosis. Neuropathol. 17: 76-79, 1997
  21. Yamatani K., et al: Increased epinephrine-induced cAMP response in severely diabetic BB/W rat liver. Endocrine J. 44: 725-732, 1997
  22. Igarashi M., et al: BAY w6228 suppresses accumulation of macrophages in balloon-induced intimal thickening of rabbit carotid artery. Atherosclerosis 128: 251-254, 1977
  23. Igarashi M., et al: Depolymerized holothurian glycosaminoglycan (DHG) prevents neointimal formation in balloon-injected rat carotid artery. Atherosclerosis 129: 27-31, 1997
  24. Daimon M., et al: Identification of a human cDNA homologue to the Drosophila translocation protein 1 (Dtrp 1). Biochem. Biophys. Res. Commun. 230: 100-104, 1997
  25. Igarashi M., et al: Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAY w6228, and its inhibitory effect on vascular smooth muscle cell growth. Brit J Pharmacol 120: 1172-1178, 1997
  26. Daimon M., et al: NIDDM with a ceruloplasmin gene mutation. Diabetes Care 20: 678, 1997
  27. Mabe K., et al: Case report: Interferon induced coma in Sheehanâćs syndrome. J. Gastroenterol. Hepatol. 12: 551-553, 1997
  28. Tominaga M., et al: Slight but significant improvement of insulin resistance of Wistar fatty rats by treatment with a disacchridase inhibitor, AO-128. Tohoku J Exp Med 181: 353-360, 1997
  29. Tominaga M., et al: Effect of thiazolidinediones on insulin resistance of non-insulin-dependent diabetes mellitus model rats. Yamagata Med J 15: 35-43, 1997
  30. Daimon M., et al: A novel missense mutation in exon 4 of the human coproporphyrinogen oxidase gene in two patients with hereditary coproporphyria. Hum Genet 99: 199-201, 1997
  31. Hayashi T., et al: sulfated polysaccharide form the leaves of Artemisia princeps activates heparin cofactor II independently of the Lys 173 and Arg 189 residues of heparin cofactor II. Thromb Res. 87: 105-112, 1997
  32. Hayashi T., et al: G to A transition at nucleotide 2110 in the human platelet glycoprotein (GP) IX gene resulting in Ala139 (ACC) to Thr (GCC) substitution. Jpn J Human Genet 42: 369-371, 1997
  33. Hayashi T., et al: Corrected DNA sequence of the platelet glycoprotein IX gene. Thrombo Haemostas 77: 1034-1035, 1997
  34. Tajima K., et al: Immunohistochemical detection of bone morphogenetic protein-2 and transforming growth factor beta-1 in tracheopathia osteochondroplastica. Virchows Arch 431: 359-363, 1997

Contact to mdaimon@med.id.yamagata-u.ac.jp for further information.